Crinetics stock rating reiterated by Oppenheimer following Palsonify approval
PositiveFinancial Markets

Crinetics Pharmaceuticals has received a positive stock rating from Oppenheimer following the approval of its drug Palsonify. This endorsement is significant as it reflects confidence in the company's growth potential and the efficacy of its new treatment, which could address unmet medical needs. Investors may see this as a promising sign for future performance.
— Curated by the World Pulse Now AI Editorial System